Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Pitney Bowes Ups The Ante In E-commerce With Consumer Connect

Published 03/04/2019, 08:54 PM
Updated 07/09/2023, 06:31 AM

Pitney Bowes Inc. (NYSE:PBI) recently introduced Consumer Connect solution. The latest marketing solution focuses on enhancing post-purchase experience of buyers, encompassing on-time delivery, punctual refunds, standard brand packaging, among other relevant attributes.

With self-service Consumer Connect, customers can track shipments, receive relevant notifications and avail easy returns.

Consequently, the enhanced customer engagement is anticipated to benefit retailers. The retailers can also utilize Consumer Connect to provide customers with seamless returns and other attractive post-purchase deals to increase customer loyalty further.

Overall, with enhanced post-checkout experience, the solution is aimed at improving brand value of retailers.

Further, Pitney Bowes noted that Consumer Connect is being demonstrated at Shoptalk, from March 3-6 at the Venetian in Las Vegas, NV.



Coming to share price performance, Pitney Bowes stock has plunged 40.4% in the past year, compared with the industry’s decline of 25%.

Expanding E-commerce Solutions Portfolio: A Key Catalyst

With an aim to address evolving consumer tastes and preferences, retailers are increasingly looking to provide sturdy engagement solutions to boost customer retention rates and expand clientele.

The high-growth retailers keep into account minute details of a consumer’s shopping journey and take initiatives to enhance it. The company’s efforts to strengthen its Global Ecommerce business with new solutions, bodes well in this regard.

Per Pitney Bowes Global Ecommerce Study, “90% of online shoppers in the US will take an action that can hurt a retailer’s brand in response to a bad post-purchase experience.” The study also reveals that 30% of millennials will reveal poor post-purchase experience, publicly via social media, which is likely to affect the retailer’s brand reputation.

We believe the aforementioned factors favor the prospects of Consumer Connect marketing solution. The incremental adoption of the latest offering is expected to boost the top line going ahead.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Notably, Pitney Bowes reported Global Ecommerce revenues of $304.3 million in the last reported quarter, improving 15.3% year over year. The segment benefited from strong performance in parcel and fulfillment volumes. Moreover, 23% revenue growth on a year-over-year basis in Newgistics aided segment performance.

Wrapping Up

Pitney Bowes is benefiting from adoption of digital commerce solutions. Strength in company’s Global Ecommerce and Presort Services domain bodes well.

However, increasing expenditure in strategic areas, like Global Ecommerce and Commerce Cloud products, is expected to limit margin expansion, at least in the near term. Moreover, the company has a leveraged balance sheet which remains a concern.

Furthermore, competition from notable players in the digital commerce domain, including Oracle (NYSE:ORCL) , salesforce.com, among others, remains a headwind.

Zacks Rank & Key Picks

Currently, Pitney Bowes carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader technology sector are Synopsys, Inc. (NASDAQ:SNPS) and Symantec Corporation (NASDAQ:SYMC) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Synopsys and Symantec have a long-term earnings growth rate of 10% and 7.9%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Synopsys, Inc. (SNPS): Free Stock Analysis Report

Symantec Corporation (SYMC): Free Stock Analysis Report

Oracle Corporation (ORCL): Free Stock Analysis Report

Pitney Bowes Inc. (PBI): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.